Cecilia Radkiewicz

ORCID: 0000-0003-0683-1537
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Gastric Cancer Management and Outcomes
  • Esophageal Cancer Research and Treatment
  • Lung Cancer Treatments and Mutations
  • Helicobacter pylori-related gastroenterology studies
  • Global Cancer Incidence and Screening
  • Colorectal Cancer Screening and Detection
  • Gastrointestinal Tumor Research and Treatment
  • Bladder and Urothelial Cancer Treatments
  • Pancreatic and Hepatic Oncology Research
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Multiple and Secondary Primary Cancers
  • Gallbladder and Bile Duct Disorders
  • Cancer Risks and Factors
  • Lymphoma Diagnosis and Treatment
  • Neuroendocrine Tumor Research Advances
  • Eosinophilic Esophagitis
  • Urinary and Genital Oncology Studies
  • Adrenal and Paraganglionic Tumors
  • Pancreatitis Pathology and Treatment
  • Neuroblastoma Research and Treatments
  • BRCA gene mutations in cancer
  • Cancer Genomics and Diagnostics
  • Lung Cancer Diagnosis and Treatment
  • CNS Lymphoma Diagnosis and Treatment
  • Palliative Care and End-of-Life Issues

Karolinska University Hospital
2022-2025

Karolinska Institutet
2017-2025

Saint Göran Hospital
2023-2025

Stockholm South General Hospital
2019

Aim To in detail delineate sex differences non-small cell lung cancer outcome and investigate possible underlying drivers. Methods We performed a nationwide, population-based cohort study using data on all incident cases of squamous carcinoma (n = 10,325) adenocarcinoma 23,465) recorded the Swedish Lung Cancer Register 2002–2016. Flexible parametric models were applied to compute adjusted female-to-male hazard ratios (aHRs) standardized survival proportions over follow-up including age,...

10.1371/journal.pone.0219206 article EN cc-by PLoS ONE 2019-06-27

It is well established that the male sex associated with increased risk for, as poorer survival of, most cancers. A similar pattern has been described in lymphomas but not yet comprehensively assessed. In this nationwide population-based cohort study, we used Swedish Lymphoma Register to investigate differences lymphoma subtype incidence and excess mortality adults (age 18-99) diagnosed 2000-2019. Male-to-female rate ratios (IRRs) (EMRs) adjusted for age calendar year were predicted using...

10.1002/ajh.26744 article EN cc-by-nc-nd American Journal of Hematology 2022-09-30

Helicobacter pylori infection is associated with a decreased risk of esophageal adenocarcinoma, and the decreasing prevalence such might contribute to increasing incidence this tumor. We examined hypothesis that eradication treatment H increases adenocarcinoma.

10.1053/j.gastro.2024.03.016 article EN cc-by Gastroenterology 2024-03-19

Studies from Western countries suggest that early-onset biliary tract cancer, a rare malignancy originating the bile ducts (cholangiocarcinoma) or gallbladder, is increasing. We performed population-based cohort study to outline age trends in cancer incidence Sweden.All patients with excluding non-biliary chiefly hepatocellular histopathology, recorded Swedish Cancer Register year 1993-2019 and at 20-84 were included. Analyses stratified by anatomical subtype; intrahepatic, perihilar,...

10.1016/j.ejca.2022.08.032 article EN cc-by European Journal of Cancer 2022-09-26

It is unknown if the reduction in expected number of cancer cases diagnosed during Swedish holidays are due to diagnostic delays, how different cancers affected, and season diagnosis influences long-term survival. We aimed quantify seasonal trends incidence excess mortality for a wide range malignancies, requiring more or less urgent clinical management.This nationwide cohort study included all residents aged 20-84 1990-2019. Incidence relative survival pancreatic, colorectal, lung,...

10.1080/0284186x.2023.2178325 article EN cc-by-nc-nd Acta Oncologica 2023-02-01

There is a lack of comprehensive reports on time trends in synchronous prostate and rectal cancers. To address this, we conducted the largest cohort study to date assess these population-based setting. We included all adult (ages 18-99) men with incident cancer Swedish Cancer Register 1993-2019. Age-standardized incidence rates (ASIRs) per 100,000 male population year were calculated compared ASIR (± 6 months from diagnosis) cancer. Age-adjusted synchronous-to-general rate ratios (IRRs)...

10.2340/1651-226x.2025.42592 article EN cc-by Acta Oncologica 2025-03-07

Advanced age is a consistent risk factor for cancer; nonetheless, cancer incidence typically declines after 75-85 most solid tumors.To delineate the true age-incidence pattern, we performed population-based cohort study using Swedish Cancer Register data from 1970-2014 on nine common, adult (age 20-99) cancers categorized as requiring high (pancreatic, lung, non-meningioma brain), medium (anorectal, urinary bladder, non-Hodgkin lymphoma), and low (melanoma skin, breast, prostate) diagnostic...

10.1158/1055-9965.epi-21-0797 article EN Cancer Epidemiology Biomarkers & Prevention 2021-10-19

Early-onset adenocarcinomas of different sites are increasing in high-income countries, data on esophagogastric adenocarcinoma sparse.We performed a Swedish population-based cohort study over 1993 to 2019 delineate differences incidence and survival early-onset (age 20-54 years) compared with later-onset (55-99 esophageal, cardia, noncardia gastric adenocarcinoma. Temporal trends were quantified as annual percentage changes (APC) excess mortality rate ratios (EMRR) using Poisson regression...

10.1158/1055-9965.epi-23-0169 article EN Cancer Epidemiology Biomarkers & Prevention 2023-05-04

The clinical importance of intraductal papillary mucinous neoplasm (IPMN) have increased last decades. Long-term survival after resection for invasive IPMN (inv-IPMN) compared to conventional pancreatic ductal adenocarcinoma (PDAC) is not thoroughly delineated.This study, based on the Swedish national and periampullary cancer registry aims elucidate outcome inv-IPMN PDAC.All patients ≥18 years age resected PDAC in Sweden between 2010 2019 were included. Clinicopathological variables...

10.1016/j.pan.2022.12.003 article EN cc-by-nc-nd Pancreatology 2022-12-08

BACKGROUND: Neoadjuvant cisplatin-based chemotherapy is standard care prior to radical cystectomy in patients with muscle-invasive bladder cancer (MIBC). OBJECTIVE: To assess efficacy and safety of two commonly used neoadjuvant schedules different total doses dose-intensities gemcitabine cisplatin (GC). METHODS: Data were collected retrospectively from all treated between 2010 2018 according clinical routine at seven centres Sweden Denmark. Patients received three cycles a 4-week schedule...

10.3233/blc-211556 article EN other-oa Bladder Cancer 2021-12-20

Incidence and mortality are default measures to describe cancer trends. Mortality compounds incidence survival but not age at death. We calculated years of life lost (YLL) due 1 the 10 solid tumors causing most deaths (lung, colorectal, prostate, pancreatic, breast, hepatobiliary, urinary, central nervous system, gastric, melanoma) using Swedish National Cancer Cause Death Registers. Comparing YLL with in 2019, lung (43 152 YLL) colorectal (32 340 remained top, pancreatic was upranked fourth...

10.1093/jncics/pkad038 article EN cc-by JNCI Cancer Spectrum 2023-05-02

<p>Early- (20-49) and later-onset (50-99) esophagogastric adenocarcinoma age-standardized incidence rate per 100,000 person-years by calendar period age-adjusted annual percentage change over 1993-2019, with 95% confidence intervals (CI).</p>

10.1158/1055-9965.27029398 preprint EN 2024-09-16

<p>Esophagogastric adenocarcinoma subtypes according to the International Classification of Diseases for Oncology 2nd revision (ICD-O-2).</p>

10.1158/1055-9965.27029404.v1 preprint EN 2024-09-16

<p>Early- (age 20-54 years, solid) and later-onset 55-99 dashed line) esophagogastric adenocarcinoma excess mortality rate (EMR) per 1,000 person-years over 5 years from diagnosis.</p>

10.1158/1055-9965.27029407.v1 preprint EN 2024-09-16

<p>Early- (age 20-54 years) and later-onset (55-99 esophagogastric adenocarcinoma incidence rate (IR) per 100,000 person-years over years 1993-2019, comparing empirical estimates (dots), modeled linear predictions with no breakpoint (blue solid line), together including one year (red line) identified using piecewise regression.</p>

10.1158/1055-9965.27029410.v1 preprint EN 2024-09-16

<p>Sex distribution, numbers (n) and percentages (%) in early- (age 20-54 years) later-onset 55-84 esophagogastric adenocarcinoma patients diagnosed years 2007-2019.</p>

10.1158/1055-9965.27029392.v1 preprint EN 2024-09-16

<p>Early-to-later-onset esophagogastric adenocarcinoma excess mortality rate ratios (EMRR) in patients diagnosed years 2007-2019, exploring effect modification by sex (upper panel) and cancer stage (lower panel), with 95% confidence intervals (CI), model fit compared using the likelihood-ratio test (p-value).</p>

10.1158/1055-9965.27029389.v1 preprint EN 2024-09-16

<p>Early- (age 20-54 years) and later-onset 55-99 esophagogastric adenocarcinoma age-standardized incidence rate (ASIR) per 100,000 person-years in men (blue) women (red), presented as mean ASIR by calendar period, empirical estimates, modeled linear predictions over years 1993-2019.</p>

10.1158/1055-9965.27029413.v1 preprint EN 2024-09-16

<p>Early- (20-49) and later-onset (50-99) esophagogastric adenocarcinoma age-standardized incidence rate per 100,000 person-years by calendar period age-adjusted annual percentage change over 1993-2019, with 95% confidence intervals (CI).</p>

10.1158/1055-9965.27029398.v1 preprint EN 2024-09-16

<p>5-year relative survival in early- (age 20-49 years) and later-onset 50-84 esophagogastric adenocarcinoma diagnosed years 2007-2019 together with early-to-later-onset excess mortality rate ratios (EMRR) 95% confidence intervals (CI).</p>

10.1158/1055-9965.27029395.v1 preprint EN 2024-09-16

<p>Distribution, numbers (n) and percentages (%), of clinicopathological characteristics in early- (age 20-49 years) later-onset 50-99 esophagogastric adenocarcinoma.</p>

10.1158/1055-9965.27029401.v1 preprint EN 2024-09-16

<div>Abstract<p>Background: Early-onset adenocarcinomas of different sites are increasing in high-income countries, data on esophagogastric adenocarcinoma sparse. Methods: We performed a Swedish population-based cohort study over 1993-2019 to delineate differences incidence and survival early-onset (age 20-54 years) compared later-onset (55-99 esophageal, cardia, non-cardia gastric adenocarcinoma. Temporal trends were quantified as annual percentage changes (APC) excess mortality...

10.1158/1055-9965.c.6662482.v3 preprint EN 2024-09-16
Coming Soon ...